European Journal of Clinical Microbiology

, Volume 3, Issue 2, pp 96–107 | Cite as

Antiherpes drugs: Promises and pitfalls

  • E. de Clercq
Review

Abstract

In recent years several selective antiherpes drugs have been developed which all show great promise for the systemic and topical treatment of herpes simplex virus and varicella-zoster virus infections. These new antiherpes agents include acyclovir, bromovinyldeoxyuridine, fluoroiodoaracytosine and phosphonoformate. Acyclovir has already been licensed for both topical and systemic use, and it is expected that other compounds will follow soon. Although this new generation of antiherpes drugs suffer from some drawbacks, i.e. narrow spectrum of activity, inefficacy during virus latency, and the possible emergence of drug-resistant virus strains, these limitations by no means outweigh the potentials of these drugs in the therapy and prophylaxis of herpesvirus infections in humans.

Keywords

Internal Medicine Virus Infection Herpes Simplex Virus Strain Acyclovir 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hirsch, M. S., Schooley, R. T.: Treatment of herpesvirus infections (I). New England Journal of Medicine 1983, 309: 963–970.PubMedCrossRefGoogle Scholar
  2. 2.
    Hirsch, M. S., Schooley, R. T.: Treatment of herpesvirus infections (II). New England Journal of Medicine 1983, 309: 1034–1038.PubMedCrossRefGoogle Scholar
  3. 3.
    Whitley, R. J., Soong, S.-J., Dolin, R., Galasso, G. J., Ch'ien, L. T., Alford, C. A., the Collaborative Study Group: Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitis. New England Journal of Medicine 1977, 297: 289–294.PubMedCrossRefGoogle Scholar
  4. 4.
    Whitley, R. J., Soong, S.-J., Hirsch, M. S., Karchmer, A. W., Dolin, R., Galasso, G., Dunnick, J. K., Alford, C. A., the NIAID Collaborative Antiviral Study Group: Herpes simplex encephalitis. Vidarabine therapy and diagnostic problems. New England Journal of Medicine 1981, 304: 313–318.PubMedCrossRefGoogle Scholar
  5. 5.
    Whitley, R. J., Nahmias, A. J., Soong, S.-J., Galasso, G. G., Fleming, C. L., Alford, C. A.: Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980, 66: 495–501.PubMedGoogle Scholar
  6. 6.
    Whitley, R. J., Ch'ien, L. T., Dolin, R., Galasso, G. J., Alford, C. A., the Collaborative Study Group: Adenine arabinoside therapy of herpes zoster in the immunosupptessed NIAID collaborative antiviral study. New England Journal of Medicine 1976, 294: 1193–1199.PubMedCrossRefGoogle Scholar
  7. 7.
    Whitley, R. J., Soong, S.-J., Dolin, R., Betts, R., Linnemann, C., Alford, C. A., the NIAID Collaborative Antiviral Study Group: Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. New England Journal of Medicine 1982, 307: 971–975.PubMedCrossRefGoogle Scholar
  8. 8.
    Vince, R., Daluge, S.: Carbocyclic arabinosyladenine, an adenosine deaminase resistant antiviral agent. Journal of Medicinal Chemistry 1977, 20: 612–613.CrossRefPubMedGoogle Scholar
  9. 9.
    Vince, R., Daluge, S., Lee, H., Shannon, W. M., Arnett, G., Schafer, T. W., Nagabhushan, T. L., Reichert, P., Tsai, H.: Carbocyclic arabinofuranosyladenine (cyclaradine): efficacy against genital herpes in guinea pigs. Science 1983, 221: 1405–1406.PubMedGoogle Scholar
  10. 10.
    Shannon, W. M., Westbrook, L., Arnett, G., Daluge, S., Lee, H., Vince, R.: Comparison of the efficacy of vidarabine, its carbocyclic analog (cyclaradine), and cyclaradine-5′-methoxyacetate in the treatment of herpes simplex virus type 1 encephalitis in mice. Antimicrobial Agents and Chemotherapy 1983, 24: 538–543.PubMedGoogle Scholar
  11. 11.
    Jones, B. R., Coster, D. J., Fison, P. N., Thompson, G. M., Cobo, L. M., Falcon, M. G.: Efficacy of acycloguanosine (Wellcome 24 8U) against herpes-simplex corneal ulcers. Lancet 1979, i: 243–244.CrossRefGoogle Scholar
  12. 12.
    Mindel, A., Adler, M. W., Sutherland, S., Fiddian, A. P.: Intravenous acyclovir treatment for primary genital herpes. Lancet 1982, i: 697–700.CrossRefGoogle Scholar
  13. 13.
    Corey, L., Nahmias, A. J., Guinan, M. E., Benedetti, J. K., Critchlow, C. W., Holmes, K. K.: A trial of topical acyclovir in genital herpes simplex virus infections. New England Journal of Medicine 1982, 306: 1313–1319.PubMedCrossRefGoogle Scholar
  14. 14.
    Nilsen, A. E., Aasen, T., Halsos, A. M., Kinge, B. R., Tjøtta, E. A. L., Wikström, K., Fiddian, A. P.: Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982, ii: 571–573.CrossRefGoogle Scholar
  15. 15.
    Reichman, R. C., Badger, G. J., Guinan, M. E., Nahmias, A. J., Keeney, R. E., Davis, L. G., Ashikaga, T., Dolin, R.: Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. Journal of Infectious Diseases 1983, 147: 336–340.PubMedGoogle Scholar
  16. 16.
    Bryson, Y. J., Dillon, M., Lovett, M., Acuna, G., Taylor, S., Cherry, J. D., Johnson, B. L., Wiesmeier, E., Growdon, W., Creagh-Kirk, T., Keeney, R.: Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. New England Journal of Medicine 1983, 308: 916–921.PubMedCrossRefGoogle Scholar
  17. 17.
    Spruance, S. L., Schnipper, L. E., Overall, J. C., Kern, E. R., Wester, B., Modlin, J., Wenerstrom, G., Burton, C., Arndt, K. A., Chiu, G. L., Crumpacker, C. S.: Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol. Journal of Infectious Diseases 1982, 146: 85–90.PubMedGoogle Scholar
  18. 18.
    Fiddian, A. P., Yeo, J. M., Stubbings, R., Dean, D.: Successful treatment of herpes labialis with topical acyclovir. British Medical Journal 1983, 286: 1699–1701.PubMedGoogle Scholar
  19. 19.
    Mitchell, C. D., Bean, B., Gentry, S. R., Groth, K. E., Boen, J. R., Balfour, H. H.: Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients. Lancet 1981, i: 1389–1392.CrossRefGoogle Scholar
  20. 20.
    Chou, S., Gallagher, J. G., Merigan, T. C.: Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections. Lancet 1981, i: 1392–1394.CrossRefGoogle Scholar
  21. 21.
    Wade, J. C., Newton, B., McLaren, C., Flournoy, N., Keeney, R. E., Meyers, J. D.: Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Annals of Internal Medicine 1982, 96: 265–269.PubMedGoogle Scholar
  22. 22.
    Balfour, H. H., Bean, B., Laskin, O. L., Ambinder, R. F., Meyers, J. D., Wade, J. C., Zaia, J. A., Aeppli, D., Kirk, L. E., Segreti, A. C., Keeney, R. E., the Burroughs Wellcome Collaborative Acyclovir Study Group: Acyclovir halts progression of herpes zoster in immunocompromised patients. New England Journal of Medicine 1983, 308: 1448–1453.PubMedCrossRefGoogle Scholar
  23. 23.
    Peterslund, N. A., Seyer-Hansen, K., Ipsen, J., Esmann, V., Schonheyder, H., Juhl, H.: Acyclovir in herpes zoster. Lancet 1981, ii: 827–830.CrossRefGoogle Scholar
  24. 24.
    Bean, B., Braun, C., Balfour, H. H., Jr.: Acyclovir therapy for acute herpes zoster. Lancet 1982, ii: 118–121.CrossRefGoogle Scholar
  25. 25.
    Saral, R., Burns, W. H., Laskin, O. L., Santos, G. W., Lietman, P. S.: Acyclovir prophylaxis of herpes-simplex -virus infections. New England Journal of Medicine 1981, 305: 63–67.PubMedCrossRefGoogle Scholar
  26. 26.
    Gluckman, E., Lotsberg, J., Devergie, A., Zhao, X. M., Melo, R., Gomez-Morales, M., Nebout, T., Mazeron, M. C., Perol, Y.: Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983, ii: 706–708.CrossRefGoogle Scholar
  27. 27.
    Strauss, S. E., Seidlin, M., Takiff, H. E.: Suppression of recurrent genital herpes with oral acyclovir. Clinical Research 1983, 31: 543A.Google Scholar
  28. 28.
    Colla, L., De Clercq, E., Busson, R., Vanderhaeghe, H.: Synthesis and antiviral activity of water-soluble esters of acyclovir (9-((2-hydroxyethoxy)methyl)guanine). Journal of Medicinal Chemistry 1983, 26: 602–604.CrossRefPubMedGoogle Scholar
  29. 29.
    Smith, K. O., Galloway, K. S., Kennell, W. L., Ogilvie, K. K., Radatus, B. K.: A new nucleoside analog, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrobial Agents and Chemotherapy 1982, 22: 55–61.PubMedGoogle Scholar
  30. 30.
    Ashton, W. T., Karkas, J. D., Field, A. K., Tolman, R. L.: Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG). Biochemical and Biophysical Research Communications 1982, 108: 1716–1721.PubMedGoogle Scholar
  31. 31.
    Martin, J. C., Dvorak, C. A., Smee, D. F., Matthews, T. R., Verheyden, J. P. H.: 9-((1,3-dihydroxy-2-proproxy)methyl)guanine: a new potent and selective antiherpes agent. Journal of Medicinal Chemistry 1983, 26: 759–761.CrossRefPubMedGoogle Scholar
  32. 32.
    Smee, D. F., Martin, J. C., Verheyden, J. P. H., Matthews, T. R.: Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrobial Agents and Chemotherapy 1983, 23: 676–682.PubMedGoogle Scholar
  33. 33.
    Cheng, Y.-C., Huang, E.-S., Lin, J.-C., Mar, E.-C., Pagano, J. S., Dutschman, G. E., Grill, S. P.: Unique spectrum of activity of 9-((l,3-dihydroxy-2-propoxy)methyl)guanine against herpesvirusesin vitro and its mode of action against herpes simplex virus type 1. Proceedings of the National Academy of Sciences of the United States of America 1983, 80: 2767–2770.PubMedGoogle Scholar
  34. 34.
    Field, A. K., Davies, M. E., DeWitt, C., Perry, H. C., Liou, R., Germershausen, J., Karkas, J. D., Ashton, W. T., Johnston, D. B. R., Tolman, R. L.: 9-(2-Hydroxy-1-(hydroxymethyl)ethoxy)methylguanine: a selective inhibitor of herpes group virus replication. Proceedings of the National Academy of Sciences of the United States of America 1983, 80: 4139–4143.PubMedGoogle Scholar
  35. 35.
    Mar, E.-C., Cheng, Y.-C., Huang, E.-S.: Effect of 9-(1,3- dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrobial Agents and Chemotherapy 1983, 24: 518–521.PubMedGoogle Scholar
  36. 36.
    DeClercq, E.: The antiviral spectrum of BVdU ((E)-5-(2-bromovinyl)-2′-deoxyuridine). Journal of Antimicrobial Chemotherapy 1984, Supplement (in press).Google Scholar
  37. 37.
    Maudgal, P. C., Missotten, L., De Clercq, E., Descamps, J., De Meuter, E.: Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the topical treatment of herpes simplex keratitis. Graefes Archiv für klinische und experimentelle Ophthalmologie 1981, 216: 261–268.CrossRefGoogle Scholar
  38. 38.
    De Clercq, E., Degreef, H., Wildiers, J., De Jonge, G., Drochmans, A., Descamps, J., De Somer, P.: Oral (E)-5-(2-bromovinyl)-2′deoxyuridine in severe herpes zoster. British Medical Journal 1980, 281: 1178.PubMedGoogle Scholar
  39. 39.
    Wildiers,J., DeClercq, E.: Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine treatment of severe herpes zoster in cancer patients. European Journal of Cancer and Clinical Oncology 1984 (in press).Google Scholar
  40. 40.
    Benoit, Y., Laureys, G., Delbeke, M.-J., De Clercq, E.: Oral BVDU treatment of varicella-zoster infections in children with cancer. European Journal of Pediatrics 1984 (in press).Google Scholar
  41. 41.
    Maudgal, P. C., Dralands, L., Lamberts, L., De Clercq, E., Descamps, I., Missotten, L.: Preliminary results of oral BVDU treatment of herpes zoster ophthalmicus. Bulletin de la Société belge d'Ophtalmologie 1981, 193: 49–56.PubMedGoogle Scholar
  42. 42.
    Young, C. W., Schneider, R., Leyland-Jones, B., Armstrong, D., Tan, C. T. C., Lopez, C., Watanabe, K. A., Fox, J. J., Philips, F. S.: Phase I evaluation of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection. Cancer Research 1983, 43: 5006–5009.PubMedGoogle Scholar
  43. 43.
    Helgstrand, E., Eriksson, B., Johansson, N. G., Lannerö, B., Larsson, A., Misiorny, A., Noren, J. O., Sjöberg, B., Stenberg, K., Stening, G., Stridh, S., Öberg, B., Alenius, S., Philipson, L.: Trisodium phosphonoformate, a new antiviral compound. Science 1978, 201: 819–821.PubMedGoogle Scholar
  44. 44.
    Alenius, S., Berg, M., Broberg, F., Eklind, K., Lindborg, B., Öberg, B.: Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. Journal of Infectious Diseases 1982, 145: 569–573.PubMedGoogle Scholar
  45. 45.
    De Clercq, E., Descamps, J., Ogata, M., Shigeta, S.: In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrobial Agents and Chemotherapy 1982, 21: 33–38.PubMedGoogle Scholar
  46. 46.
    Shigeta, S., Yokota, T., Iwabuchi, T., Baba, M., Konno, K., Ogata, M., De Clercq, E.: Comparative efficacy of antiherpes drugs against various strains of varicellazoster virus. Journal of Infectious Diseases 1983, 147: 576–584.PubMedGoogle Scholar
  47. 47.
    Soike, K. F., Felsenfeld, A. D., Gibson, S., Gerone, P. J.: Ineffectiveness of adenine arabinoside and adenjne arabinoside 5′-monophosphate in simian varicella infection. Antimicrobial Agents and Chemotherapy 1980, 18: 142–147.PubMedGoogle Scholar
  48. 48.
    Soike, K. F., Felsenfeld, A. D., Gerone, P. J.: Acyclovir treatment of experimental simian varicella infection of monkeys. Antimicrobial Agents and Chemotherapy 1981, 20: 291–297.PubMedGoogle Scholar
  49. 49.
    Soike, K. F., Gibson, S., Gerone, P. J.: Inhibition of simian varicella virus infection of African green monkeys by (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU). Antiviral Research 1981, 1: 325–337.CrossRefGoogle Scholar
  50. 50.
    Lin, J.-C., Smith, M. C., Cheng, Y.-C., Pagano, J. S.: Epstein-Barr virus: inhibition of replication by three new drugs. Science 1983, 221: 578–579.PubMedGoogle Scholar
  51. 51.
    Elion, G. B., Furman, P. A., Fyfe, J. A., de Miranda, P., Beauchamp, L., Schaeffer, H. J.: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences of the United States of America 1977, 74: 5716–5720.PubMedGoogle Scholar
  52. 52.
    Schaeffer, H. J., Beauchamp, L., de Miranda, P., Elion, G. B., Bauer, D. J., Collins, P.: 9-(2-hydroxyethoxymethyl)guanine activity against viruses of the herpes group. Nature 1978, 272: 583–585.CrossRefPubMedGoogle Scholar
  53. 53.
    De Clercq, E., Descamps, J., De Somer, P., Barr, P. J., Jones, A. S., Walker, R. T.: (E)-5-(2-bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proceedings of the National Academy of Sciences of the United States of America 1979, 76: 2947–2951.PubMedGoogle Scholar
  54. 54.
    De Clercq, E., Descamps, J., Verhelst, G., Walker, R. T., Jones, A. A., Torrence, P. F., Shugar, D.: Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. Journal of Infectious Diseases 1980, 141: 563–574.PubMedGoogle Scholar
  55. 55.
    Crumpacker, C. S., Schnipper, L. E., Zaia, J. A., Levin, M. J.: Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrobial Agents and Chemotherapy 1979, 15: 642–645.PubMedGoogle Scholar
  56. 56.
    Biron, K. K., Elion, G. B.: In vitro susceptibility of varicella-zoster virus to acyclovir. Antimicrobial Agents and Chemotherapy 1980, 18: 443–447.PubMedGoogle Scholar
  57. 57.
    Smith, C. A., Wigdahl, B., Rapp, F.: Synergistic antiviral activity of acyclovir and interferon on human cytomegalovirus. Antimicrobial Agents and Chemotherapy 1983, 24: 325–332.PubMedGoogle Scholar
  58. 58.
    Balfour, H. H., Bean, B., Mitchell, C. D., Sachs, G. W., Boen, J. R., Edelman, C. K.: Acyclovir in immunocompromised patients with cytomegalovirus disease: a controlled trial at one institution. American Journal of Medicine 1982, 73 (1A): 241–248.PubMedGoogle Scholar
  59. 59.
    Colby, B. M., Shaw, J. E., Elion, G. B., Pagano, J. S.: Effect of acyclovir (9-(2-hydroxyethoxymethyl)guanine) on Epstein-Barr virus DNA replication. Journal of Virology 1980, 34: 560–568.PubMedGoogle Scholar
  60. 60.
    Hanto, D. W., Frizzera, G., Gajl-Peczalska, K. J., Sakamoto, K., Purtilo, D. T., Balfour, H. H., Simmons, R. L., Najarian, J. S.: Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. New England Journal of Medicine 1982, 306: 913–918.PubMedCrossRefGoogle Scholar
  61. 61.
    Pagano, J. S., Sixbey, J. W., Lin, J.-C.: Acyclovir and Epstein-Barr virus infection. Journal of Antimicrobial Chemotherapy 1983, 12, Supplement B: 113–121.PubMedGoogle Scholar
  62. 62.
    Zhang, Z.-X., Liu, Y.-X., Chen, H.-S., Allaudeen, H. S., De Clercq, E.: Effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine on several parameters of Epstein-Barr virus infection. Journal of General Virology 1984, 65: 37–46.PubMedGoogle Scholar
  63. 63.
    Sim, I. S.: Oral and topical treatment of experimental HSV-1 genital herpes with E-5-(2-bromovinyl)-2′-deoxyuridine. Journal of Antimicrobial Chemotherapy 1984, Supplement (in press).Google Scholar
  64. 64.
    Colacino, J. M., Lopez, C.: Efficacy and selectivity of some nucleoside analogs as antihuman cytomegalovirus agents. Antimicrobial Agents and Chemotherapy 1983, 24: 505–508.PubMedGoogle Scholar
  65. 65.
    De Clercq, E.: Commentary: Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochemical Pharmacology 1984 (in press).Google Scholar
  66. 66.
    Park, N.-H., Pavan-Langston, D., McLean, S. L.: Acyclovir in oral and ganglionic herpes simplex virus infections. Journal of Infectious Diseases 1979, 140: 802–806.PubMedGoogle Scholar
  67. 67.
    Klein, R. J., DeStefano, E., Friedman-Kien, A. E., Brady, E.: Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice. Antimicrobial Agents and Chemotherapy 1981, 19: 937–939.PubMedGoogle Scholar
  68. 68.
    Field, H. J., De Clercq, E.: Effects of oral treatment with acyclovir and bromovinyldeoxyuridine on the establishment and maintenance of latent herpes simplex virus infection in mice. Journal of General Virology 1981, 56: 259–265.PubMedGoogle Scholar
  69. 69.
    Park, N.-H., Pavan-Langston, D., Boisjoly, H. M., De Clercq, E.: Chemotherapeutic efficacy of E-5-(2-bromovinyl)-2′-deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice. Journal of Infectious Diseases 1982, 145: 909–913.PubMedGoogle Scholar
  70. 70.
    Field, H. J., Wildy, P.: Recurrent herpes simplex: the outlook for systemic antiviral agents. British Medical Journal 1981, 282: 1821–1822.PubMedCrossRefGoogle Scholar
  71. 71.
    Klein, R. J.: The pathogenesis of acute, latent and recurrent herpes simplex virus infections. Archives of Virology 1982, 72: 143–168.CrossRefPubMedGoogle Scholar
  72. 72.
    Maudgal, P. C., De Clercq, E., Missotten, L.: Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections. Antiviral Research 1984 (in press).Google Scholar
  73. 73.
    Coen, D. M., Schaffer, P. A.: Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proceedings of the National Academy of Sciences of the United States of America 1980, 77: 2265–2269.PubMedGoogle Scholar
  74. 74.
    Schnipper, L. E., Crumpacker, C. S.: Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci. Proceedings of the National Academy of Sciences of the United States of America 1980, 77: 2270–2273.PubMedGoogle Scholar
  75. 75.
    Darby, G., Field, H. J., Salisbury, S. A.: Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance. Nature 1981, 289: 81–83.CrossRefPubMedGoogle Scholar
  76. 76.
    Furman, P. A., Coen, D. M., St. Clair, M. H., Schaffer, P. A.: Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities. Journal of Virology 1981, 40: 936–941.PubMedGoogle Scholar
  77. 77.
    Larder, B. A., Darby, G.: Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant. Journal of Virology 1982, 42: 649–658.PubMedGoogle Scholar
  78. 78.
    Larder, B. A., Cheng, Y.-C., Darby, G.: Characterization of abnormal thymidine kinases induced by drugresistant strains of herpes simplex virus type 1. Journal of General Virology 1983, 64: 523–532.PubMedCrossRefGoogle Scholar
  79. 79.
    Larder, B. A., Darby, G.: Virus drug-resistance: mechanisms and consequences. Antiviral Research 1984 (in press).Google Scholar
  80. 80.
    Field, H. J.: A perspective on resistance to acyclovir in herpes simplex virus. Journal of Antimicrobial Chemotherapy 1983, 12 Supplement B: 129–135.PubMedGoogle Scholar
  81. 81.
    Dekker, C., Ellis, M. N., McLaren, C., Hunter, G., Rogers, J., Barry, D. W.: Virus resistance in clinical practice. Journal of Antimicrobial Chemotherapy 1983, 12 Supplement B: 137–152.PubMedGoogle Scholar
  82. 82.
    Crumpacker, C. S., Schnipper, L. E., Marlowe, S. I., Kowalsky, P. N., Hershey, B. J., Levin, M. J.: Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. New England Journal of Medicine 1982, 306: 343–346.PubMedCrossRefGoogle Scholar
  83. 83.
    Burns, W. H., Saral, R., Santos, G. W., Laskin, O. L., Lietnam, P. S., McLaren, C., Barry, D. W.: Isolation and characterisation of resistant herpes simplex virus after acyclovir therapy Lancet 1982, i: 421–423.CrossRefGoogle Scholar
  84. 84.
    Field, H. J., Darby, G.: Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1980, 17: 209–216.PubMedGoogle Scholar
  85. 85.
    Klein, R. J., Friedman-Kien, A. E., De Stefano, E.: Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants. Infection and Immunity 1981, 34: 693–701.PubMedGoogle Scholar
  86. 86.
    Field, H., McMillan, A., Darby, G.: The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs. Journal of Infectious Diseases 1981, 143: 281–285.PubMedGoogle Scholar
  87. 87.
    Field, H., Neden, J.: Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir. Antiviral Research 1982, 2: 243–254.CrossRefPubMedGoogle Scholar
  88. 88.
    Boisjoly, H. M., Park, N.-H., Pavan-Langston, D., De Clercq, E.: Herpes simplex acyclovir-resistant mutant in experimental keratouveitis. Archives of Ophthalmology 1983, 101: 1782–1786.PubMedGoogle Scholar
  89. 89.
    De Miranda, P., Krasny, H. C., Page, D. A., Elion, G. B.: Species differences in the disposition of acyclovir. American Journal of Medicine 1982, 73: 31–35.PubMedGoogle Scholar
  90. 90.
    Desgranges, C., Razaka, G., Rabaud, M., Bricaud, H., Balzarini, J., De Clercq, E.: Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted 2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets. Biochemical Pharmacology 1983, 32: 3583–3590.CrossRefPubMedGoogle Scholar
  91. 91.
    Desgranges, C., Razaka, G., Drouillet, F., Bricaud, H., Herdewijn, P., De Clercq, E.: Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2′-deoxyuridinein vivo. Nucleic Acids Research 1984, 12: 2081–2090.PubMedGoogle Scholar
  92. 92.
    Sacks, S. L., Scullard, G. H., Pollard, R. B., Gregory, P. B., Robinson, W. S., Merigan, T. C.: Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination. Antimicrobial Agents and Chemotherapy 1982, 21: 93–100.PubMedGoogle Scholar
  93. 93.
    Chou, T.-C., Feinberg, A., Grant, A. J., Vidai, P., Reichman, U., Watanabe, K. A., Fox, J. J., Philips, F. S.: Pharmacological disposition and metabolic fate of 2′-fluoro-5-iodo-1-β-D-arabinofuranosylcytosine in mice and rats. Cancer Research 1981, 41: 3336–3342.PubMedGoogle Scholar
  94. 94.
    Philips, F. S., Feinberg, A., Chou, T.-C., Vidai, P. M., Su, T.-L., Watanabe, K. A., Fox, J. J.: Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine. Cancer Research 1983, 43: 3619–3627.PubMedGoogle Scholar
  95. 95.
    De Clercq, E., Zhang, Z.-X., Sim, I. S.: Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2′-deoxyuridine in mice. Antimicrobial Agents and Chemotherapy 1982, 22: 421–425.PubMedGoogle Scholar
  96. 96.
    Schinazi, R. F., Peters, J., Sokol, M. K., Nahmias, A. J.: Therapeutic activities of 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrobial Agents and Chemotherapy 1983, 24: 95–103.PubMedGoogle Scholar
  97. 97.
    Helgstrand, E., Flodh, H., Lernestedt, J.-O., Lundström, J., Öberg, B.: Trisodium phosphonoformate: antiviral activities, safety evaluation and preliminary clinical results. In: Collier, L. H., Oxford, J. (ed.): Developments in antiviral therapy. Academic Press, London, 1980, p. 63–83.Google Scholar

Copyright information

© Vieweg Publishing 1984

Authors and Affiliations

  • E. de Clercq
    • 1
  1. 1.Rega Institute for Medical ResearchKatholieke Universiteit LeuvenLeuvenBelgium

Personalised recommendations